
    
      Brentuximab vedotin will be administered as an outpatient IV infusion on day 1 of each 21-day
      cycle. Bendamustine will be given as an outpatient infusion on days 1 and 2 of a 21-day
      cycle. Patients may receive prophylactic pegfilgrastim on day 3 of each cycle, or filgrastim
      for 5 to 10 days, per investigator's discretion. Patients can receive a maximum of 6 cycles
      of therapy.
    
  